High Circulating Endothelial Progenitor Levels Associated with Poor Survival of Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib Combined with Metronomic Chemotherapy

Publisher： Karger

E-ISSN： 1423-0232|81|2|98-103

ISSN： 0030-2414

Source： Oncology, Vol.81, Iss.2, 2011-10, pp. : 98-103

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Predictors of survival in patients with advanced hepatocellular carcinoma who permanently discontinued sorafenib

By  

HEPATOLOGY, Vol. 62, Iss. 3, 2015-09 ,pp. : 784-791

John Wiley & Sons Inc

Access to resources Recommend Favorite

Changes in plasma vascular endothelial growth factor at 8 weeks after sorafenib administration as predictors of survival for advanced hepatocellular carcinoma

By  

CANCER, Vol. 120, Iss. 2, 2014-01 ,pp. : 229-237

John Wiley & Sons Inc

Access to resources Recommend Favorite

Elevated Plasma Fibrinogen Levels Are Associated with a Poor Prognosis in Patients with Hepatocellular Carcinoma

By  

Oncology, Vol. 85, Iss. 5, 2013-11 ,pp. : 269-277

Karger

Access to resources Recommend Favorite

Efficacy, Safety, and Survival Factors for Sorafenib Treatment in Japanese Patients with Advanced Hepatocellular Carcinoma

By  

Oncology, Vol. 84, Iss. 2, 2012-11 ,pp. : 108-114

Karger

Access to resources Recommend Favorite

Pancreatic Atrophy in Hepatocellular Carcinoma Patients Receiving Long-Term Treatment with Sorafenib

By  

Oncology, Vol. 89, Iss. 2, 2015-04 ,pp. : 88-94

Karger

Access to resources Recommend Favorite